Events & Presentations

Date	Event Details	Remind Me
Sep 26, 2023 10:30 AM EDT	2023 Cantor Fitzgerald Global Healthcare Conference Listen to webcast	Add to Outlook Add to Google Calendar

Date	Event Details
Apr 8 - Apr 13, 2022	American Association for Cancer Research Annual Meeting 2022 (AACR) Supporting Materials: AACR 2022 ARO-HIF2 Poster 1.6 MB View Additional Information Title: Targeting HIF2a with siRNA: From preclinical models to the clinic Authors: Yuanqing Ma, et al.
Mar 30 - Apr 3, 2022	31st Conference of the Asian Pacific Association for the Study of the Liver (APASL 2022) Supporting Materials: APASL 2022 JNJ-3989 in Healthy Chinese 2.5 MB APASL 2022 JNJ-3989 in Hepatic Impaired 176.6 KB APASL 2022 JNJ-3989 927.4 KB View Additional Information Title: Pharmacokinetics and Safety of JNJ-73763989, an RNA Interference Therapy for Hepatitis B Virus, in Moderately Hepatically Impaired Participants Authors: Thomas N. Kakuda, et al. Title: Pharmacokinetics, Safety, and Tolerability of the siRNA JNJ-73763989 in Healthy Chinese Adult Participants Authors: Haiyan Li, et al. Title: Short interfering RNA JNJ-3989 combination therapy in chronic hepatitis B shows potent reduction of all viral markers but no correlate was identified for HBsAg reduction and baseline factors Authors: Edward Gane, et al.
Feb 17 - Feb 19, 2022	2022 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU) Supporting Materials: Initial results from the phase 1 study of ARO-HIF2 to silence HIF2-alpha in patients with advanced ccRCC (AROHIF21001) 1.5 MB View Additional Information San Francisco, CA and online Presentation Details: Title: Initial results from the phase 1 study of ARO-HIF2 to silence HIF2-alpha in patients with advanced ccRCC (AROHIF21001) Authors: James Brugarolas, et al. Session: Poster Session C: Renal Cell Cancer; Adrenal, Penile, Urethral, and Testicular Cancers Abstract Number: 339 Poster Number: F9
Feb 2, 2022 4:30 PM EST	Arrowhead Pharmaceuticals 2022 First Quarter Results Listen to webcast Supporting Materials: Prepared Remarks 206.2 KB
Dec 3, 2021	18th Global Cardiovascular Clinical Trialists Forum Supporting Materials: View Presentation 1.1 MB View Additional Information James Hamilton, MD, MBA, Arrowhead’s senior vice president of discovery & translational medicine, will participate in a panel discussion titled, “Developments in Hypertriglyceridemia Trials”
Dec 2, 2021 1:00 PM EST	4th Annual Evercore ISI HealthCONx Conference Listen to webcast View Additional Information Chris Anzalone, Ph.D., Arrowhead’s president and CEO, will participate in a fireside chat presentation
Nov 30, 2021	Piper Sandler 33rd Annual Healthcare Conference Listen to webcast View Additional Information Chris Anzalone, Ph.D., Arrowhead’s president and CEO, will participate in a fireside chat presentation
Nov 22, 2021 4:30 PM EST	Arrowhead Pharmaceuticals 2021 Year End Results Listen to webcast Supporting Materials: Prepared Remarks 210.1 KB
Nov 16, 2021 11:50 AM EST	Jefferies London Healthcare Conference View Additional Information Chris Anzalone, Ph.D., Arrowhead’s president and CEO, will participate in a fireside chat presentation
Nov 13 - Nov 17, 2021	American Heart Association (AHA) Scientific Sessions 2021 Supporting Materials: American Heart Association (AHA) Scientific Sessions 2021 659.9 KB View Additional Information Title: ARO-APOC3, an Investigational RNAi Therapeutic, Shows Similar Efficacy and Safety in Genetically Confirmed FCS and Non-FCS Participants with Severe Hypertriglyceridemia Authors: Christie Ballantyne, presenting on behalf of Peter Clifton, et al. Session: The Future of Lipidology: Novel and Emerging Interventions for Lipid Disorders